Previous close | 52.82 |
Open | 54.78 |
Bid | 52.06 x N/A |
Ask | 53.22 x N/A |
Day's range | 54.36 - 54.78 |
52-week range | 47.41 - 60.92 |
Volume | |
Avg. volume | 11 |
Market cap | N/A |
Beta (5Y monthly) | 0.69 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Incyte ( NASDAQ:INCY ) First Quarter 2024 Results Key Financial Results Revenue: US$880.9m (up 8.9% from 1Q 2023). Net...
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.